García-Martín Estela, Pernía-López Sagrario, Martínez-Ortega Pilar A, Monje Beatriz, Ruiz-Martínez Cristina, Sanjurjo-Saez María
Department of Pharmacy, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
Eur J Hosp Pharm. 2019 Jul;26(4):226-228. doi: 10.1136/ejhpharm-2017-001293. Epub 2017 Aug 16.
Hereditary haemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu disease, is a rare, vascular, autosomal dominant disorder. The purpose of this paper is to describe the efficacy and safety of treatment with intranasal bevacizumab in HHT. A 42-year-old woman with HHT presented with frequent episodes of epistaxis. Iron studies showed anaemia of iron deficiency from chronic blood loss. Because of the frequent epistaxis (Epistaxis Severity Score (ESS) 6.76) and varying haemoglobin levels (Hb range: 7.7-9.9g/dL) her doctors sought treatment with intranasal bevacizumab. This treatment was prescribed at the hospital pharmacy department in a laminar flow hood. 2.5 mL (25 mg) were placed in a nasal spray bottle. The recommended dosage was twice a day for two consecutive months. Nasal treatment seemed to control her epistaxis, and no adverse effects were reported. She only had a few further minor episodes of epistaxis, which were easily controlled (ESS 3.44). The haemoglobin levels evreached normal levels (Hb range: 12.8-14.1g/dL).
遗传性出血性毛细血管扩张症（HHT），又称奥斯勒-韦伯-伦杜病，是一种罕见的、血管性的常染色体显性遗传病。本文旨在描述鼻内使用贝伐单抗治疗HHT的疗效和安全性。一名42岁的HHT女性患者经常鼻出血。铁代谢检查显示因慢性失血导致缺铁性贫血。由于频繁鼻出血（鼻出血严重程度评分（ESS）为6.76）以及血红蛋白水平波动（血红蛋白范围：7.7 - 9.9g/dL），她的医生寻求鼻内使用贝伐单抗进行治疗。该治疗药物由医院药房在层流罩中配制。将2.5 mL（25 mg）药物置于鼻喷雾瓶中。推荐剂量为连续两个月每天两次。鼻腔治疗似乎控制了她的鼻出血，且未报告不良反应。她仅又出现了几次轻微鼻出血发作，很容易得到控制（ESS为3.44）。血红蛋白水平达到正常范围（血红蛋白范围：12.8 - 14.1g/dL）。
